Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.69 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | HTT | P42858 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13789842 | 0.81 | PCSK9 (0.65) | MAPTPCSK9LMNAHTTMAPK1 | |
| SCHEMBL12604460 | 0.80 | PCSK9 (1.00) | MAPTPCSK9LMNAHTTMAPK1 | |
| SCHEMBL7438053 | 0.80 | MAPT (0.41) | MAPTPCSK9LMNAHTTMAPK1 | |
| SCHEMBL12604422 | 0.79 | MAPT (1.00) | MAPTPCSK9LMNAHTTMAPK1 | |
| SCHEMBL13789710 | 0.78 | MAPK1 (1.00) | MAPTPCSK9LMNAHTTMAPK1 | |
| SCHEMBL18991478 | 0.77 | MAPT (0.52) | MAPTLMNAHTTMAPK1USP2 | |
| SCHEMBL18990271 | 0.77 | MAPT (0.66) | MAPTLMNAHTTUSP2SMN1; SMN2 | |
| SCHEMBL13789803 | 0.76 | MAPK1 (0.98) | MAPTPCSK9LMNAHTTMAPK1 | |
| SCHEMBL7440073 | 0.76 | GAA (0.47) | MAPTPCSK9HTTMAPK1HSD17B10 | |
| SCHEMBL31575414 | 0.75 | RAB9A (0.78) | MAPTPCSK9LMNAHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149480-A1 | METHODS OF USING PDE V INHIBITORS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE | SCHERING CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-20090149480-A1 | METHODS OF USING PDE V INHIBITORS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE | SCHERING CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-7531544-B2 | Xanthine phosphodiesterase V inhibitors | SCHERING CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531544-B2 | Xanthine phosphodiesterase V inhibitors | SCHERING CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105282-A1 | METHODS OF TREATING BENIGN PROSTATIC HYPERPLASIA OR LOWER URINARY TRACT SYMPTOMS BY USING PDE 5 INHIBITORS | SCHERING-PLOUGH CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105282-A1 | METHODS OF TREATING BENIGN PROSTATIC HYPERPLASIA OR LOWER URINARY TRACT SYMPTOMS BY USING PDE 5 INHIBITORS | SCHERING-PLOUGH CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20080058354-A1 | Xanthine Phosphodiesterase V Inhibitors | SCHERING CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-7268141-B2 | Xanthine phosphodiesterase V inhibitors | SCHERING CORPORATION (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268141-B2 | Xanthine phosphodiesterase V inhibitors | SCHERING CORPORATION (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070037831-A1 | Methods of using PDE 5 inhibitors for the treatment of congestive heart failure | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-20070037831-A1 | Methods of using PDE 5 inhibitors for the treatment of congestive heart failure | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-20070004745-A1 | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors | SCHERING-PLOUGH CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20070004745-A1 | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors | SCHERING-PLOUGH CORPORATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037831-A1 | Methods of using PDE 5 inhibitors for the treatment of congestive heart failure | PDE5A, PDE3A, PDE3B | MAPT 4874/4885PCSK9 185/4885LMNA 2390/4885 |
| US-20070004745-A1 | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors | PDE5A, BPHL, PDE12 | MAPT 3172/4885PCSK9 202/4885LMNA 2822/4885 |
| US-20080058354-A1 | Xanthine Phosphodiesterase V Inhibitors | PDE5A, PDE3B, PDE3A | MAPT 3766/4885PCSK9 224/4885LMNA 3505/4885 |
| US-20090105282-A1 | METHODS OF TREATING BENIGN PROSTATIC HYPERPLASIA OR LOWER URINARY TRACT SYMPTOMS BY USING PDE 5 INHIBITORS | PDE5A, BPHL, PDE12 | MAPT 3172/4885PCSK9 202/4885LMNA 2822/4885 |
| US-20090149480-A1 | METHODS OF USING PDE V INHIBITORS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE | PDE5A, PDE3A, PDE3B | MAPT 4875/4885PCSK9 146/4885LMNA 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.